PAVmed Inc. (PAVM)
| Market Cap | 144.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.06M |
| Shares Out | 48.38M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.01 |
| Previous Close | $2.07 |
| Change ($) | -0.06 |
| Change (%) | -2.90% |
| Day's Open | 2.06 |
| Day's Range | 1.96 - 2.15 |
| Day's Volume | 2,165,636 |
| 52-Week Range | 1.37 - 3.29 |
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...
PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...
The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue m...
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, t...
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, to...
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, to...
NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, to...
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the C...
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...
Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin
PAVMed Is About To Enter The Commercialization Phase
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
PAVmed: Small Medical Device Maker With New FDA Approval And Multiple Catalysts
NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it h...
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that...
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it h...
Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires mult...
Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal canc...
Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ p...
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it ha...
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an upd...
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2019 Results - Earnings Call Transcript
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology
Unprecedented six-month maintenance-free implant duration achieved
PAVM has a market cap of $35 million with one FDA approved device and another expected by early 2020. The TAM for these devices is $3B+ in the U.S. alone.
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2019 Results - Earnings Call Transcript
Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time
NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2019 Results - Earnings Call Transcript
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2018 Results and Business Update- Earnings Call Transcript
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2018 Results and Business Update- Earnings Call Transcript
About PAVM
PAVmed operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation devi... [Read more...]
| Industry Medical Devices | IPO Date Apr 28, 2016 |
| CEO Dr. Lishan Aklog M.D. | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol PAVM |
Analyst Forecasts
According to 3 analysts, the average rating for PAVmed stock is "Strong Buy." The 12-month stock price forecast is 5.08, which is an increase of 152.74% from the latest price.